NVS NVO NVO AZN-GB GSK GSK SMMT XPH IBB Novartis has signed a deal worth up to $7. 8 billion, in the latest of a flurry of tie-ups between Big Pharma and Chinese biotechs.
Read the original report for the complete account of this story.
POLARIS INSIGHTS
Big Pharma turns to China for new drugs as patent cliff drives multibillion-dollar deals
